{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34485538", "DateCompleted": {"Year": "2022", "Month": "01", "Day": "24"}, "DateRevised": {"Year": "2022", "Month": "01", "Day": "24"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "08", "Day": "25"}], "Language": ["eng"], "ELocationID": ["9483433", "10.1155/2021/9483433"], "Journal": {"ISSN": "2314-7156", "JournalIssue": {"Volume": "2021", "PubDate": {"Year": "2021"}}, "Title": "Journal of immunology research", "ISOAbbreviation": "J Immunol Res"}, "ArticleTitle": "A Perspective on <i>Withania somnifera</i> Modulating Antitumor Immunity in Targeting Prostate Cancer.", "Pagination": {"StartPage": "9483433", "MedlinePgn": "9483433"}, "Abstract": {"AbstractText": ["Medicinal plants serve as a lead source of bioactive compounds and have been an integral part of day-to-day life in treating various disease conditions since ancient times. Withaferin A (WFA), a bioactive ingredient of <i>Withania somnifera</i>, has been used for health and medicinal purposes for its adaptogenic, anti-inflammatory, and anticancer properties long before the published literature came into existence. Nearly 25% of pharmaceutical drugs are derived from medicinal plants, classified as dietary supplements. The bioactive compounds in these supplements may serve as chemotherapeutic substances competent to inhibit or reverse the process of carcinogenesis. The role of WFA is appreciated to polarize tumor-suppressive Th1-type immune response inducing natural killer cell activity and may provide an opportunity to manipulate the tumor microenvironment at an early stage to inhibit tumor progression. This article signifies the cumulative information about the role of WFA in modulating antitumor immunity and its potential in targeting prostate cancer."], "CopyrightInformation": "Copyright \u00a9 2021 Seema Dubey et al."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pathology, MCW Cancer Center and Prostate Cancer Center of Excellence, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA."}], "LastName": "Dubey", "ForeName": "Seema", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pathology, MCW Cancer Center and Prostate Cancer Center of Excellence, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA."}], "LastName": "Singh", "ForeName": "Manohar", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA."}], "LastName": "Nelson", "ForeName": "Ariel", "Initials": "A"}, {"Identifier": ["0000-0002-0905-0886"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pathology, MCW Cancer Center and Prostate Cancer Center of Excellence, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA."}], "LastName": "Karan", "ForeName": "Dev", "Initials": "D"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Egypt", "MedlineTA": "J Immunol Res", "NlmUniqueID": "101627166", "ISSNLinking": "2314-7156"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents, Phytogenic"}, {"RegistryNumber": "0", "NameOfSubstance": "Withanolides"}, {"RegistryNumber": "L6DO3QW4K5", "NameOfSubstance": "withaferin A"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Antineoplastic Agents, Phytogenic"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug effects", "immunology"], "DescriptorName": "Killer Cells, Natural"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["drug effects", "immunology", "pathology"], "DescriptorName": "Prostate"}, {"QualifierName": ["drug therapy", "immunology", "pathology"], "DescriptorName": "Prostatic Neoplasms"}, {"QualifierName": ["drug effects", "immunology"], "DescriptorName": "Th1 Cells"}, {"QualifierName": ["drug effects", "immunology"], "DescriptorName": "Tumor Microenvironment"}, {"QualifierName": ["chemistry"], "DescriptorName": "Withania"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Withanolides"}], "CoiStatement": "The authors have no financial conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Culp M. B., Soerjomataram I., Efstathiou J. A., Bray F., Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. European Urology. 2020;77(1):38\u201352. doi: 10.1016/j.eururo.2019.08.005.", "ArticleIdList": ["10.1016/j.eururo.2019.08.005", "31493960"]}, {"Citation": "Newman D. J., Cragg G. M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products. 2020;83(3):770\u2013803. doi: 10.1021/acs.jnatprod.9b01285.", "ArticleIdList": ["10.1021/acs.jnatprod.9b01285", "32162523"]}, {"Citation": "Matsushita M., Fujita K., Nonomura N. Influence of diet and nutrition on prostate cancer. International Journal of Molecular Sciences. 2020;21(4):p. 1447. doi: 10.3390/ijms21041447.", "ArticleIdList": ["10.3390/ijms21041447", "PMC7073095", "32093338"]}, {"Citation": "Lin P. H., Aronson W., Freedland S. J. Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Medicine. 2015;13(3) doi: 10.1186/s12916-014-0234-y.", "ArticleIdList": ["10.1186/s12916-014-0234-y", "PMC4286914", "25573005"]}, {"Citation": "Schlag E. M., McIntosh M. S. Ginsenoside content and variation among and within American ginseng (Panax quinquefolius L.) populations. Phytochemistry. 2006;67(14):1510\u20131519. doi: 10.1016/j.phytochem.2006.05.028.", "ArticleIdList": ["10.1016/j.phytochem.2006.05.028", "16839573"]}, {"Citation": "Elsakka M., Grigorescu E., Stanescu U., Stanescu U., Dorneanu V. New data referring to chemistry of Withania somnifera species. Revista Medico-Chirurgical\u0103\u0306 a Societ\u0103\u0306\u0163\u031cii de Medici \u015f\u0327i Naturali\u015f\u0327ti din Ia\u015f\u0327i. 1990;94(2):385\u2013387.", "ArticleIdList": ["2100857"]}, {"Citation": "Sabina E. P., Chandal S., Rasool M. K. Inhibition of monosodium urate crystal-induced inflammation by withaferin a. Journal of Pharmacy & Pharmaceutical Sciences. 2008;11(4):46\u201355. doi: 10.18433/j35k58.", "ArticleIdList": ["10.18433/j35k58", "19183513"]}, {"Citation": "Munagala R., Kausar H., Munjal C., Gupta R. C. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis. 2011;32(11):1697\u20131705. doi: 10.1093/carcin/bgr192.", "ArticleIdList": ["10.1093/carcin/bgr192", "21859835"]}, {"Citation": "Stan S. D., Hahm E. R., Warin R., Singh S. V. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Research. 2008;68(18):7661\u20137669. doi: 10.1158/0008-5472.CAN-08-1510.", "ArticleIdList": ["10.1158/0008-5472.CAN-08-1510", "PMC2562581", "18794155"]}, {"Citation": "Sivasankarapillai V. S., Madhu Kumar Nair R., Rahdar A., et al. Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera. Environmental Science and Pollution Research International. 2020;27(21):26025\u201326035. doi: 10.1007/s11356-020-09028-0.", "ArticleIdList": ["10.1007/s11356-020-09028-0", "32405942"]}, {"Citation": "Hahm E. R., Kim S. H., Singh K. B., Singh K., Singh S. V. A comprehensive review and perspective on anticancer mechanisms of withaferin A in breast cancer. Cancer Prevention Research (Philadelphia, Pa.) 2020;13(9):721\u2013734. doi: 10.1158/1940-6207.CAPR-20-0259.", "ArticleIdList": ["10.1158/1940-6207.CAPR-20-0259", "PMC7501947", "32727824"]}, {"Citation": "Hassannia B., Logie E., Vandenabeele P., Vanden Berghe T., Vanden Berghe W., Withaferin A. Withaferin A: from ayurvedic folk medicine to preclinical anti-cancer drug. Biochemical Pharmacology. 2020;173, article 113602 doi: 10.1016/j.bcp.2019.08.004.", "ArticleIdList": ["10.1016/j.bcp.2019.08.004", "31404528"]}, {"Citation": "Zhang X., Samadi A. K., Roby K. F., Timmermann B., Cohen M. S. Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide withaferin A. Gynecologic Oncology. 2012;124(3):606\u2013612. doi: 10.1016/j.ygyno.2011.11.044.", "ArticleIdList": ["10.1016/j.ygyno.2011.11.044", "PMC3278582", "22188785"]}, {"Citation": "Srinivasan S., Ranga R. S., Burikhanov R., Han S. S., Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Research. 2007;67(1):246\u2013253. doi: 10.1158/0008-5472.CAN-06-2430.", "ArticleIdList": ["10.1158/0008-5472.CAN-06-2430", "17185378"]}, {"Citation": "Behl T., Sharma A., Sharma L., et al. Exploring the multifaceted therapeutic potential of withaferin A and its derivatives. Biomedicines. 2020;8(12):p. 571. doi: 10.3390/biomedicines8120571.", "ArticleIdList": ["10.3390/biomedicines8120571", "PMC7762146", "33291236"]}, {"Citation": "Kim G., Kim T. H., Hwang E. H., Chang K. T., Hong J. J., Park J. H. Withaferin A inhibits the proliferation of gastric cancer cells by inducing G2/M cell cycle arrest and apoptosis. Oncology Letters. 2017;14(1):416\u2013422. doi: 10.3892/ol.2017.6169.", "ArticleIdList": ["10.3892/ol.2017.6169", "PMC5494816", "28693185"]}, {"Citation": "Chang H.-W., Li R.-N., Wang H.-R., et al. Withaferin A induces oxidative stress-mediated apoptosis and DNA damage in oral cancer cells. Frontiers in Physiology. 2017;8:p. 634. doi: 10.3389/fphys.2017.00634.", "ArticleIdList": ["10.3389/fphys.2017.00634", "PMC5594071", "28936177"]}, {"Citation": "Stan S. D., Zeng Y., Singh S. V. Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutrition and Cancer. 2008;60(Supplement 1):51\u201360. doi: 10.1080/01635580802381477.", "ArticleIdList": ["10.1080/01635580802381477", "PMC2597540", "19003581"]}, {"Citation": "Tang Q., Ren L., Liu J., et al. Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4-ATF3-CHOP axis. Cell Proliferation. 2020;53(1, article e12706) doi: 10.1111/cpr.12706.", "ArticleIdList": ["10.1111/cpr.12706", "PMC6985693", "31642559"]}, {"Citation": "Okamoto S., Tsujioka T., Suemori S. I., et al. Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression. Cancer Science. 2016;107(9):1302\u20131314. doi: 10.1111/cas.12988.", "ArticleIdList": ["10.1111/cas.12988", "PMC5021033", "27311589"]}, {"Citation": "Batra A., Winquist E. Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer. Expert Opinion on Emerging Drugs. 2018;23(4):271\u2013282. doi: 10.1080/14728214.2018.1547707.", "ArticleIdList": ["10.1080/14728214.2018.1547707", "30422005"]}, {"Citation": "Roy R. V., Suman S., Das T. P., Luevano J. E., Damodaran C. Withaferin A, a steroidal lactone from Withania somnifera, induces mitotic catastrophe and growth arrest in prostate cancer cells. Journal of Natural Products. 2013;76(10):1909\u20131915. doi: 10.1021/np400441f.", "ArticleIdList": ["10.1021/np400441f", "PMC4144448", "24079846"]}, {"Citation": "Nishikawa Y., Okuzaki D., Fukushima K., et al. Withaferin A induces cell death selectively in androgen-independent prostate cancer cells but not in normal fibroblast cells. PLoS One. 2015;10(7, article e0134137) doi: 10.1371/journal.pone.0134137.", "ArticleIdList": ["10.1371/journal.pone.0134137", "PMC4521694", "26230090"]}, {"Citation": "Choi B. Y., Kim B.-W. Withaferin-A inhibits colon cancer cell growth by blocking STAT3 transcriptional activity. Journal of Cancer Prevention. 2015;20(3):185\u2013192. doi: 10.15430/JCP.2015.20.3.185.", "ArticleIdList": ["10.15430/JCP.2015.20.3.185", "PMC4597807", "26473157"]}, {"Citation": "Kakar S. S., Worth C. A., Wang Z., Carter K., Ratajczak M., Gunjal P. DOXIL when combined with withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer. Journal of Cancer Stem Cell Research. 2016;4(2):p. 1. doi: 10.14343/JCSCR.2016.4e1002.", "ArticleIdList": ["10.14343/JCSCR.2016.4e1002", "PMC5033248", "27668267"]}, {"Citation": "Lee T.-J., Um H. J., Park J.-W., Choi K. S., Kwon T. K. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radical Biology and Medicine. 2009;46(12):1639\u20131649. doi: 10.1016/j.freeradbiomed.2009.03.022.", "ArticleIdList": ["10.1016/j.freeradbiomed.2009.03.022", "19345731"]}, {"Citation": "Nagalingam A., Kuppusamy P., Singh S. V., Sharma D., Saxena N. K. Mechanistic elucidation of the antitumor properties of withaferin A in breast cancer. Cancer Research. 2014;74(9):2617\u20132629. doi: 10.1158/0008-5472.CAN-13-2081.", "ArticleIdList": ["10.1158/0008-5472.CAN-13-2081", "PMC4009451", "24732433"]}, {"Citation": "Ping Dou Q. A Zonder J. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Current Cancer Drug Targets. 2014;14(6):517\u2013536.", "ArticleIdList": ["PMC4279864", "25092212"]}, {"Citation": "Ri M. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. International Journal of Hematology. 2016;104(3):273\u2013280. doi: 10.1007/s12185-016-2016-0.", "ArticleIdList": ["10.1007/s12185-016-2016-0", "27169614"]}, {"Citation": "Choi M. J., Park E. J., Min K. J., Park J.-W., Kwon T. K. Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells. Toxicology In Vitro. 2011;25(3):692\u2013698. doi: 10.1016/j.tiv.2011.01.010.", "ArticleIdList": ["10.1016/j.tiv.2011.01.010", "21266191"]}, {"Citation": "Ghosh K., De S., Mukherjee S., Das S., Ghosh A. N., Sengupta S. B. Withaferin A induced impaired autophagy and unfolded protein response in human breast cancer cell-lines MCF-7 and MDA-MB-231. Toxicology In Vitro. 2017;44:330\u2013338. doi: 10.1016/j.tiv.2017.07.025.", "ArticleIdList": ["10.1016/j.tiv.2017.07.025", "28782635"]}, {"Citation": "Yang H., Shi G., Dou Q. P. The tumor proteasome is a primary target for the natural anticancer compound withaferin A isolated from \u201cIndian winter cherry\u201d. Molecular Pharmacology. 2007;71(2):426\u2013437. doi: 10.1124/mol.106.030015.", "ArticleIdList": ["10.1124/mol.106.030015", "17093135"]}, {"Citation": "Duque J. L., Loughlin K. R., Adam R. M., Kantoff P., Mazzucchi E., Freeman M. R. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (S\u00e3o Paulo, Brazil) 2006;61(5):401\u2013408.", "ArticleIdList": ["17072437"]}, {"Citation": "Nordby Y., Andersen S., Richardsen E., et al. Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy. The Prostate. 2015;75(15):1682\u20131693. doi: 10.1002/pros.23048.", "ArticleIdList": ["10.1002/pros.23048", "26268996"]}, {"Citation": "McKay R. R., Zurita A. J., Werner L., et al. A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy. Journal of Clinical Oncology. 2016;34(16):1913\u20131920. doi: 10.1200/JCO.2015.65.3154.", "ArticleIdList": ["10.1200/JCO.2015.65.3154", "PMC5321094", "27044933"]}, {"Citation": "Kelly W. K., Halabi S., Carducci M., et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. Journal of Clinical Oncology. 2012;30(13):1534\u20131540. doi: 10.1200/JCO.2011.39.4767.", "ArticleIdList": ["10.1200/JCO.2011.39.4767", "PMC3383121", "22454414"]}, {"Citation": "Hoseinkhani Z., Norooznezhad F., Rastegari-Pouyani M., Mansouri K. Medicinal plants extracts with antiangiogenic activity: where is the link? Advanced Pharmaceutical Bulletin. 2020;10(3):370\u2013378. doi: 10.34172/apb.2020.045.", "ArticleIdList": ["10.34172/apb.2020.045", "PMC7335987", "32665895"]}, {"Citation": "Fan T. P., Yeh J. C., Leung K. W., Yue P. Y., Wong R. N. Angiogenesis: from plants to blood vessels. Trends in Pharmacological Sciences. 2006;27(6):297\u2013309. doi: 10.1016/j.tips.2006.04.006.", "ArticleIdList": ["10.1016/j.tips.2006.04.006", "16697473"]}, {"Citation": "Gururaj A. E., Belakavadi M., Venkatesh D. A., Marme D., Salimath B. P. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochemical and Biophysical Research Communications. 2002;297(4):934\u2013942. doi: 10.1016/S0006-291X(02)02306-9.", "ArticleIdList": ["10.1016/S0006-291X(02)02306-9", "12359244"]}, {"Citation": "Hu W. H., Duan R., Xia Y. T., et al. Binding of resveratrol to vascular endothelial growth factor suppresses angiogenesis by inhibiting the receptor signaling. Journal of Agricultural and Food Chemistry. 2019;67(4):1127\u20131137. doi: 10.1021/acs.jafc.8b05977.", "ArticleIdList": ["10.1021/acs.jafc.8b05977", "30525561"]}, {"Citation": "Mohan R., Hammers H., Bargagna-mohan P., et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis. 2004;7(2):115\u2013122. doi: 10.1007/s10456-004-1026-3.", "ArticleIdList": ["10.1007/s10456-004-1026-3", "15516832"]}, {"Citation": "Bargagna-Mohan P., Hamza A., Kim Y. E., et al. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chemistry & Biology. 2007;14(6):623\u2013634. doi: 10.1016/j.chembiol.2007.04.010.", "ArticleIdList": ["10.1016/j.chembiol.2007.04.010", "PMC3228641", "17584610"]}, {"Citation": "Prasanna Kumar S., Shilpa P., Salimath B. P. Withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor. Current Trends in Biotechnology and Pharmacy. 2009;3(2):138\u2013148."}, {"Citation": "Suman S., Das T. P., Moselhy J., et al. Oral administration of withaferin A inhibits carcinogenesis of prostate in TRAMP model. Oncotarget. 2016;7(33):53751\u201353761. doi: 10.18632/oncotarget.10733.", "ArticleIdList": ["10.18632/oncotarget.10733", "PMC5288218", "27447565"]}, {"Citation": "Das T., Suman S., Alatassi H., Ankem M., Damodaran C. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer. Cell Death & Disease. 2016;7(2):e2111\u2013e2111. doi: 10.1038/cddis.2015.403.", "ArticleIdList": ["10.1038/cddis.2015.403", "PMC4849149", "26913603"]}, {"Citation": "Moselhy J., Suman S., Alghamdi M., et al. Withaferin A inhibits prostate carcinogenesis in a PTEN-deficient mouse model of prostate cancer. Neoplasia. 2017;19(6):451\u2013459. doi: 10.1016/j.neo.2017.04.005.", "ArticleIdList": ["10.1016/j.neo.2017.04.005", "PMC5421823", "28494348"]}, {"Citation": "Chang E., Pohling C., Natarajan A., et al. AshwaMAX and withaferin A inhibits gliomas in cellular and murine orthotopic models. Journal of Neuro-Oncology. 2016;126(2):253\u2013264. doi: 10.1007/s11060-015-1972-1.", "ArticleIdList": ["10.1007/s11060-015-1972-1", "PMC5597337", "26650066"]}, {"Citation": "Sari A. N., Bhargava P., Dhanjal J. K., et al. Combination of withaferin-A and CAPE provides superior anticancer potency: bioinformatics and experimental evidence to their molecular targets and mechanism of action. Cancers (Basel) 2020;12(5):p. 1160. doi: 10.3390/cancers12051160.", "ArticleIdList": ["10.3390/cancers12051160", "PMC7281427", "32380701"]}, {"Citation": "Kim S. H., Singh K. B., Hahm E. R., Lokeshwar B. L., Singh S. V. Withania somnifera root extract inhibits fatty acid synthesis in prostate cancer cells. Journal of Traditional and Complementary Medicine. 2020;10(3):188\u2013197. doi: 10.1016/j.jtcme.2020.02.002.", "ArticleIdList": ["10.1016/j.jtcme.2020.02.002", "PMC7340880", "32670813"]}, {"Citation": "Setty Balakrishnan A., Nathan A. A., Kumar M., Ramamoorthy S., Ramia Mothilal S. K. Withania somnifera targets interleukin-8 and cyclooxygenase-2 in human prostate cancer progression. Prostate International. 2017;5(2):75\u201383. doi: 10.1016/j.prnil.2017.03.002.", "ArticleIdList": ["10.1016/j.prnil.2017.03.002", "PMC5448731", "28593171"]}, {"Citation": "Multhoff G., Molls M., Radons J. Chronic inflammation in cancer development. Frontiers in Immunology. 2011;2:p. 98.", "ArticleIdList": ["PMC3342348", "22566887"]}, {"Citation": "Greten F. R., Grivennikov S. I. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27\u201341. doi: 10.1016/j.immuni.2019.06.025.", "ArticleIdList": ["10.1016/j.immuni.2019.06.025", "PMC6831096", "31315034"]}, {"Citation": "Coussens L. M., Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860\u2013867. doi: 10.1038/nature01322.", "ArticleIdList": ["10.1038/nature01322", "PMC2803035", "12490959"]}, {"Citation": "Xu H., Hu M.-b., Bai P.-d., et al. Proinflammatory cytokines in prostate cancer development and progression promoted by high-fat diet. BioMed Research International. 2015;2015:7. doi: 10.1155/2015/249741.249741", "ArticleIdList": ["10.1155/2015/249741", "PMC4334627", "25722971"]}, {"Citation": "Hayashi T., Fujita K., Nojima S., et al. High-fat diet-induced inflammation accelerates prostate cancer growth via IL6 signaling. Clinical Cancer Research. 2018;24(17):4309\u20134318. doi: 10.1158/1078-0432.CCR-18-0106.", "ArticleIdList": ["10.1158/1078-0432.CCR-18-0106", "29776955"]}, {"Citation": "de Bono J. S., Guo C., Gurel B., et al. Prostate carcinogenesis: inflammatory storms. Nature Reviews. Cancer. 2020;20(8):455\u2013469. doi: 10.1038/s41568-020-0267-9.", "ArticleIdList": ["10.1038/s41568-020-0267-9", "32546840"]}, {"Citation": "Archer M., Dogra N., Kyprianou N. Inflammation as a driver of prostate cancer metastasis and therapeutic resistance. Cancers (Basel) 2020;12(10):p. 2984. doi: 10.3390/cancers12102984.", "ArticleIdList": ["10.3390/cancers12102984", "PMC7602551", "33076397"]}, {"Citation": "Karan D., Holzbeierlein J., Thrasher J. B. Macrophage inhibitory cytokine-1: possible bridge molecule of inflammation and prostate cancer. Cancer Research. 2009;69(1):2\u20135. doi: 10.1158/0008-5472.CAN-08-1230.", "ArticleIdList": ["10.1158/0008-5472.CAN-08-1230", "19117979"]}, {"Citation": "Terlizzi M., Casolaro V., Pinto A., Sorrentino R. Inflammasome: cancer\u2019s friend or foe? Pharmacology & Therapeutics. 2014;143(1):24\u201333. doi: 10.1016/j.pharmthera.2014.02.002.", "ArticleIdList": ["10.1016/j.pharmthera.2014.02.002", "24518102"]}, {"Citation": "Zitvogel L., Kepp O., Galluzzi L., Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nature Immunology. 2012;13(4):343\u2013351. doi: 10.1038/ni.2224.", "ArticleIdList": ["10.1038/ni.2224", "22430787"]}, {"Citation": "Karan D. Inflammasomes: emerging central players in cancer immunology and immunotherapy. Frontiers in Immunology. 2018;9:p. 3028. doi: 10.3389/fimmu.2018.03028.", "ArticleIdList": ["10.3389/fimmu.2018.03028", "PMC6315184", "30631327"]}, {"Citation": "Zhao S., Zhang Y., Zhang Q., Wang F., Zhang D. Toll-like receptors and prostate cancer. Frontiers in Immunology. 2014;5:p. 352.", "ArticleIdList": ["PMC4107957", "25101092"]}, {"Citation": "Ou T., Lilly M., Jiang W. The pathologic role of toll-like receptor 4 in prostate cancer. Frontiers in Immunology. 2018;9:p. 1188. doi: 10.3389/fimmu.2018.01188.", "ArticleIdList": ["10.3389/fimmu.2018.01188", "PMC5998742", "29928275"]}, {"Citation": "Eluard B., Thieblemont C., Baud V. NF-\u03baB in the new era of cancer therapy. Trends Cancer. 2020;6(8):677\u2013687. doi: 10.1016/j.trecan.2020.04.003.", "ArticleIdList": ["10.1016/j.trecan.2020.04.003", "32409139"]}, {"Citation": "Grosset A. A., Ouellet V., Caron C., et al. Validation of the prognostic value of NF-\u03baB p65 in prostate cancer: a retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. PLoS Medicine. 2019;16(7, article e1002847) doi: 10.1371/journal.pmed.1002847.", "ArticleIdList": ["10.1371/journal.pmed.1002847", "PMC6605640", "31265453"]}, {"Citation": "Domingo-Domenech J., Mellado B., Ferrer B., et al. Activation of nuclear factor- \u03ba B in human prostate carcinogenesis and association to biochemical relapse. British Journal of Cancer. 2005;93(11):1285\u20131294. doi: 10.1038/sj.bjc.6602851.", "ArticleIdList": ["10.1038/sj.bjc.6602851", "PMC2361509", "16278667"]}, {"Citation": "Khan H., Ullah H., Castilho P., et al. Targeting NF-\u03baB signaling pathway in cancer by dietary polyphenols. Critical Reviews in Food Science and Nutrition. 2020;60(16):2790\u20132800. doi: 10.1080/10408398.2019.1661827.", "ArticleIdList": ["10.1080/10408398.2019.1661827", "31512490"]}, {"Citation": "Marquardt J. U., Gomez-Quiroz L., Arreguin Camacho L. O., et al. Curcumin effectively inhibits oncogenic NF-\u03baB signaling and restrains stemness features in liver cancer. Journal of Hepatology. 2015;63(3):661\u2013669. doi: 10.1016/j.jhep.2015.04.018.", "ArticleIdList": ["10.1016/j.jhep.2015.04.018", "PMC4543531", "25937435"]}, {"Citation": "Liu S., Wang Z., Hu Z., et al. Anti-tumor activity of curcumin against androgen-independent prostate cancer cells via inhibition of NF-\u03baB and AP-1 pathway in vitro. Journal of Huazhong University of Science and Technology. Medical Sciences. 2011;31(4):530\u2013534. doi: 10.1007/s11596-011-0485-1.", "ArticleIdList": ["10.1007/s11596-011-0485-1", "21823017"]}, {"Citation": "Habib S. H., Makpol S., Abdul Hamid N. A., Das S., Ngah W. Z., Yusof Y. A. Ginger extract (Zingiber officinale) has anti-cancer and anti-inflammatory effects on ethionine-induced hepatoma rats. Clinics (S\u00e3o Paulo, Brazil) 2008;63(6):807\u2013813.", "ArticleIdList": ["PMC2664283", "19061005"]}, {"Citation": "Abd Wahab N. A., Lajis N. H., Abas F., Othman I., Naidu R. Mechanism of anti-cancer activity of curcumin on androgen-dependent and androgen-independent prostate cancer. Nutrients. 2020;12(3):p. 679. doi: 10.3390/nu12030679.", "ArticleIdList": ["10.3390/nu12030679", "PMC7146610", "32131560"]}, {"Citation": "Jiang L. N., Liu Y. B., Li B. H. Lycopene exerts anti-inflammatory effect to inhibit prostate cancer progression. Asian Journal of Andrology. 2019;21:p. 80. doi: 10.4103/aja.aja_70_18.", "ArticleIdList": ["10.4103/aja.aja_70_18", "PMC6337959", "30198495"]}, {"Citation": "Assar E. A., Vidalle M. C., Chopra M., Hafizi S. Lycopene acts through inhibition of I\u03baB kinase to suppress NF-\u03baB signaling in human prostate and breast cancer cells. Tumour Biology. 2016;37(7):9375\u20139385. doi: 10.1007/s13277-016-4798-3.", "ArticleIdList": ["10.1007/s13277-016-4798-3", "26779636"]}, {"Citation": "Zhao Q., Yang F., Meng L., et al. Lycopene attenuates chronic prostatitis/chronic pelvic pain syndrome by inhibiting oxidative stress and inflammation via the interaction of NF\u2010\u03baB, MAPKs, and Nrf2 signaling pathways in rats. Andrology. 2020;8(3):747\u2013755. doi: 10.1111/andr.12747.", "ArticleIdList": ["10.1111/andr.12747", "PMC7317562", "31880092"]}, {"Citation": "Gupta S. C., Kim J. H., Kannappan R., Reuter S., Dougherty P. M., Aggarwal B. B. Role of nuclear factor-\u03baB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Experimental Biology and Medicine (Maywood, N.J.) 2011;236(6):658\u2013671. doi: 10.1258/ebm.2011.011028.", "ArticleIdList": ["10.1258/ebm.2011.011028", "PMC3141285", "21565893"]}, {"Citation": "Shishodia S., Majumdar S., Banerjee S., Aggarwal B. B. Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Research. 2003;63(15):4375\u20134383.", "ArticleIdList": ["12907607"]}, {"Citation": "Oh J. H., Lee T. J., Park J. W., Kwon T. K., Withaferin A. Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-\u03baB in RAW 264.7 cells. European Journal of Pharmacology. 2008;599(1-3):11\u201317. doi: 10.1016/j.ejphar.2008.09.017.", "ArticleIdList": ["10.1016/j.ejphar.2008.09.017", "18838070"]}, {"Citation": "Dubey S., Yoon H., Cohen M. S., Nagarkatti P., Nagarkatti M., Karan D. Withaferin A associated differential regulation of inflammatory cytokines. Frontiers in Immunology. 2018;9:p. 195. doi: 10.3389/fimmu.2018.00195.", "ArticleIdList": ["10.3389/fimmu.2018.00195", "PMC5811468", "29479354"]}, {"Citation": "Naidoo D. B., Chuturgoon A. A., Phulukdaree A., Guruprasad K. P., Satyamoorthy K., Sewram V. Withania somnifera modulates cancer cachexia associated inflammatory cytokines and cell death in leukaemic THP-1 cells and peripheral blood mononuclear cells (PBMC\u2019s) BMC Complementary and Alternative Medicine. 2018;18(1):p. 126. doi: 10.1186/s12906-018-2192-y.", "ArticleIdList": ["10.1186/s12906-018-2192-y", "PMC5891897", "29631586"]}, {"Citation": "Rasool M., Varalakshmi P. Immunomodulatory role of Withania somnifera root powder on experimental induced inflammation: an in vivo and in vitro study. Vascular Pharmacology. 2006;44(6):406\u2013410. doi: 10.1016/j.vph.2006.01.015.", "ArticleIdList": ["10.1016/j.vph.2006.01.015", "16713367"]}, {"Citation": "Logie E., Vanden B. W. Tackling chronic inflammation with withanolide phytochemicals-a withaferin A perspective. Antioxidants (Basel) 2020;9(11)", "ArticleIdList": ["PMC7696210", "33182809"]}, {"Citation": "Kanak M. A., Shahbazov R., Yoshimatsu G., Levy M. F., Lawrence M. C., Naziruddin B. A small molecule inhibitor of NF\u03baB blocks ER stress and the NLRP3 inflammasome and prevents progression of pancreatitis. Journal of Gastroenterology. 2017;52(3):352\u2013365. doi: 10.1007/s00535-016-1238-5.", "ArticleIdList": ["10.1007/s00535-016-1238-5", "27418337"]}, {"Citation": "Kim J. E., Lee J. Y., Kang M. J., et al. Withaferin A inhibits Helicobacter pylori-induced production of IL-1\u03b2 in dendritic cells by regulating NF-\u03baB and NLRP3 inflammasome activation. Immune Network. 2015;15(6):269\u2013277. doi: 10.4110/in.2015.15.6.269.", "ArticleIdList": ["10.4110/in.2015.15.6.269", "PMC4700403", "26770181"]}, {"Citation": "Zhao H. M., Gao Z. W., Xie S. X., Han X., Sun Q. S. Withaferin A attenuates ovalbumin induced airway inflammation. Frontiers in Bioscience. 2019;24:576\u2013596.", "ArticleIdList": ["30468675"]}, {"Citation": "Barua A., Bradaric M. J., Bitterman P., et al. Dietary supplementation of Ashwagandha (Withania somnifera, Dunal) enhances NK cell function in ovarian tumors in the laying hen model of spontaneous ovarian cancer. American Journal of Reproductive Immunology. 2013;70(6):538\u2013550. doi: 10.1111/aji.12172.", "ArticleIdList": ["10.1111/aji.12172", "24188693"]}, {"Citation": "Fehniger T. A., Cai S. F., Cao X., et al. Acquisition of murine NK cell cytotoxicity requires the translation of a pre- existing pool of granzyme B and perforin mRNAs. Immunity. 2007;26(6):798\u2013811. doi: 10.1016/j.immuni.2007.04.010.", "ArticleIdList": ["10.1016/j.immuni.2007.04.010", "17540585"]}, {"Citation": "Smyth M. J., Cretney E., Kelly J. M., et al. Activation of NK cell cytotoxicity. Molecular Immunology. 2005;42(4):501\u2013510. doi: 10.1016/j.molimm.2004.07.034.", "ArticleIdList": ["10.1016/j.molimm.2004.07.034", "15607806"]}, {"Citation": "Malik F., Kumar A., Bhushan S., et al. Immune modulation and apoptosis induction: two sides of antitumoural activity of a standardised herbal formulation of Withania somnifera. European Journal of Cancer. 2009;45(8):1494\u20131509. doi: 10.1016/j.ejca.2009.01.034.", "ArticleIdList": ["10.1016/j.ejca.2009.01.034", "19269163"]}, {"Citation": "Muralikrishnan G., Dinda A. K., Shakeel F. Immunomodulatory effects of Withania somnifera on azoxymethane induced experimental colon cancer in mice. Immunological Investigations. 2010;39(7):688\u2013698. doi: 10.3109/08820139.2010.487083.", "ArticleIdList": ["10.3109/08820139.2010.487083", "20840055"]}, {"Citation": "Kushwaha S., Roy S., Maity R., et al. Chemotypical variations in Withania somnifera lead to differentially modulated immune response in BALB/c mice. Vaccine. 2012;30(6):1083\u20131093. doi: 10.1016/j.vaccine.2011.12.031.", "ArticleIdList": ["10.1016/j.vaccine.2011.12.031", "22182427"]}, {"Citation": "Tripathi C. D., Kushawaha P. K., Sangwan R. S., Mandal C., Misra-Bhattacharya S., Dube A. Withania somnifera chemotype NMITLI 101R significantly increases the efficacy of antileishmanial drugs by generating strong IFN- \u03b3 and IL-12 mediated immune responses in Leishmania donovani infected hamsters. Phytomedicine. 2017;24:87\u201395. doi: 10.1016/j.phymed.2016.11.012.", "ArticleIdList": ["10.1016/j.phymed.2016.11.012", "28160866"]}, {"Citation": "Griffith T. S., Kawakita M., Tian J., et al. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. Journal of the National Cancer Institute. 2001;93(13):998\u20131007. doi: 10.1093/jnci/93.13.998.", "ArticleIdList": ["10.1093/jnci/93.13.998", "11438565"]}, {"Citation": "Davis L., Kuttan G. Effect of Withania somnifera on cell mediated immune responses in mice. Journal of Experimental & Clinical Cancer Research. 2002;21(4):585\u2013590.", "ArticleIdList": ["12636106"]}, {"Citation": "Mikolai J., Erlandsen A., Murison A., et al. In vivo effects of Ashwagandha (Withania somnifera) extract on the activation of lymphocytes. Journal of Alternative and Complementary Medicine. 2009;15(4):423\u2013430. doi: 10.1089/acm.2008.0215.", "ArticleIdList": ["10.1089/acm.2008.0215", "19388865"]}, {"Citation": "Chi N., Tan Z., Ma K., Bao L., Yun Z. Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer. International Journal of Clinical and Experimental Medicine. 2014;7(10):3181\u20133192.", "ArticleIdList": ["PMC4238489", "25419348"]}, {"Citation": "Erlandsson A., Carlsson J., Lundholm M., et al. M2 macrophages and regulatory T cells in lethal prostate cancer. The Prostate. 2019;79(4):363\u2013369. doi: 10.1002/pros.23742.", "ArticleIdList": ["10.1002/pros.23742", "PMC6587459", "30500076"]}, {"Citation": "Sinha P., Ostrand-Rosenberg S. Myeloid-derived suppressor cell function is reduced by withaferin A, a potent and abundant component of Withania somnifera root extract. Cancer Immunology, Immunotherapy. 2013;62(11):1663\u20131673. doi: 10.1007/s00262-013-1470-2.", "ArticleIdList": ["10.1007/s00262-013-1470-2", "23982485"]}, {"Citation": "Fuladi S., Emami S. A., Mohammadpour A. H., Karimani A., Manteghi A. A., Sahebkar A. Assessment of Withania somnifera root extract efficacy in patients with generalized anxiety disorder: a randomized double-blind placebo-controlled trial. Current Clinical Pharmacology. 2020;15 doi: 10.2174/1574884715666200413120413.", "ArticleIdList": ["10.2174/1574884715666200413120413", "32282308"]}, {"Citation": "Lopresti A. L., Drummond P. D., Smith S. J. A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of Ashwagandha (Withania somnifera) in aging, overweight males. American Journal of Men's Health. 2019;13(2) doi: 10.1177/1557988319835985.", "ArticleIdList": ["10.1177/1557988319835985", "PMC6438434", "30854916"]}, {"Citation": "Lopresti A. L., Smith S. J., Malvi H., Kodgule R. An investigation into the stress-relieving and pharmacological actions of an Ashwagandha (Withania somnifera) extract: a randomized, double-blind, placebo-controlled study. Medicine (Baltimore) 2019;98(37, article e17186) doi: 10.1097/MD.0000000000017186.", "ArticleIdList": ["10.1097/MD.0000000000017186", "PMC6750292", "31517876"]}, {"Citation": "Chengappa K. N. R., Brar J. S., Gannon J. M., Schlicht P. J. Adjunctive use of a standardized extract of Withania somnifera (Ashwagandha) to treat symptom exacerbation in schizophrenia: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 2018;79(5) doi: 10.4088/JCP.17m11826.", "ArticleIdList": ["10.4088/JCP.17m11826", "29995356"]}, {"Citation": "Gannon J. M., Brar J., Rai A., Chengappa K. N. R. Effects of a standardized extract of Withania somnifera (Ashwagandha) on depression and anxiety symptoms in persons with schizophrenia participating in a randomized, placebo-controlled clinical trial. Annals of Clinical Psychiatry. 2019;31(2):123\u2013129.", "ArticleIdList": ["31046033"]}, {"Citation": "Choudhary D., Bhattacharyya S., Bose S. Efficacy and safety of Ashwagandha (Withania somnifera (L.) Dunal) root extract in improving memory and cognitive functions. Journal of Dietary Supplements. 2017;14(6):599\u2013612. doi: 10.1080/19390211.2017.1284970.", "ArticleIdList": ["10.1080/19390211.2017.1284970", "28471731"]}, {"Citation": "Jahanbakhsh S. P., Manteghi A. A., Emami S. A., et al. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: a randomized double-blind placebo-controlled trial. Complementary Therapies in Medicine. 2016;27:25\u201329. doi: 10.1016/j.ctim.2016.03.018.", "ArticleIdList": ["10.1016/j.ctim.2016.03.018", "27515872"]}, {"Citation": "Sharma A. K., Basu I., Singh S. Efficacy and safety of Ashwagandha root extract in subclinical hypothyroid patients: a double-blind, randomized placebo-controlled trial. Journal of Alternative and Complementary Medicine. 2018;24(3):243\u2013248. doi: 10.1089/acm.2017.0183.", "ArticleIdList": ["10.1089/acm.2017.0183", "28829155"]}, {"Citation": "Biswal B. M., Sulaiman S. A., Ismail H. C., Zakaria H., Musa K. I. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integrative Cancer Therapies. 2013;12(4):312\u2013322. doi: 10.1177/1534735412464551.", "ArticleIdList": ["10.1177/1534735412464551", "23142798"]}, {"Citation": "Pires N., Gota V., Gulia A., Hingorani L., Agarwal M., Puri A. Safety and pharmacokinetics of withaferin-A in advanced stage high grade osteosarcoma: a phase I trial. Journal of Ayurveda and Integrative Medicine. 2020;11(1):68\u201372. doi: 10.1016/j.jaim.2018.12.008.", "ArticleIdList": ["10.1016/j.jaim.2018.12.008", "PMC7125369", "30904387"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "7", "Day": "2"}, {"Year": "2021", "Month": "8", "Day": "7"}, {"Year": "2021", "Month": "9", "Day": "6", "Hour": "6", "Minute": "9"}, {"Year": "2021", "Month": "9", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "1", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "8", "Day": "25"}], "PublicationStatus": "epublish", "ArticleIdList": ["34485538", "PMC8413038", "10.1155/2021/9483433"]}}], "PubmedBookArticle": []}